Are you already a client or interested in our services? We are happy to help you.
We are happy to speak to you in person. Call us or click on the link below for more contact options and locations.
The Netherlands
0800 17 37Belgium
+32 (0)32 86 69 80Switzerland
+41 (0)43 377 11 11We are happy to speak to you in person. Call us or click on the link below for more contact options and locations.
The Netherlands
+31 (0)20 348 80 00United States of America
+1 (0)21 237 601 34Joint Global Coordinator and Joint Bookrunner
Kempen & Co acted as Joint Global Coordinator & Joint Bookrunner to SynAct Pharma in its SEK 150m Fully Guaranteed Rights Issue.
SynAct is a publicly listed Swedish biotech focused on the development of novel and first in class agonists that target the melanocortin system, which plays a pivotal role in controlling inflammatory responses. Lead candidate, AP1189, selectively stimulates the melanocortin receptors involved in anti-inflammatory and pro-resolution effects without causing immunosuppression and is studied in rheumatoid arthritis, nephrotic syndrome, and COVID-19 induced acute respiratory stress syndrome.
In the last twelve months, Kempen & Co has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include: